Articles on this Page
- 01/08/19--05:37: _Annie Zaidi: Solihu...
- 01/08/19--06:03: _What Padraig Harrin...
- 01/08/19--06:25: _Tinder Swipeout: Po...
- 01/08/19--06:43: _Stocks rally again ...
- 01/08/19--06:50: _Why so much snow fo...
- 01/08/19--08:57: _500,000 Go Missing ...
- 01/08/19--08:53: _Alps avalanche late...
- 01/08/19--09:05: _Return of the Beast...
- 01/08/19--09:04: _Geely/China autos: ...
- 01/08/19--09:55: _Reacting to EU sanc...
- 01/08/19--10:45: _Heathrow passengers...
- 01/08/19--10:45: _Drone sighting halt...
- 01/08/19--10:59: _Heathrow airport sa...
- 01/08/19--11:15: _Drone reports tempo...
- 01/08/19--11:44: _Opinion: How Merced...
- 01/08/19--16:14: _Nord Stream 2 Is Lo...
- 01/08/19--17:07: _London remains top ...
- 01/09/19--05:04: _Accommodations Plus...
- 01/09/19--05:12: _Verona Pharma Recei...
- 01/09/19--05:11: _New threat to Briti...
- 01/08/19--05:37: Annie Zaidi: Solihull Moors Ladies appoint new head coach
- 01/08/19--06:43: Stocks rally again as U.S.-China trade hopes build
- 01/08/19--06:50: Why so much snow for Europe?
- 01/08/19--08:57: 500,000 Go Missing At People’s Vote March
- 01/08/19--09:05: Return of the Beast? Britain faces new Siberian cold snap
- 01/08/19--09:04: Geely/China autos: higgledy-piggledy
- 01/08/19--10:45: Drone sighting halts flights from London's Heathrow
- 01/08/19--10:59: Heathrow airport says flights have resumed after drone disruption
- 01/08/19--11:15: Drone reports temporarily halt flights from London's Heathrow
- 01/08/19--11:44: Opinion: How Mercedes hopes to snare younger buyers for the CLA
- 01/08/19--16:14: Nord Stream 2 Is Losing Support In Germany
- 01/08/19--17:07: London remains top destination for European tech funding
BBC Local News: Birmingham and Black Country -- Annie Zaidi - thought to be the only hijab-wearing Uefa B coach in Europe - becomes Solihull Moors Ladies' head coach.
Reported by BBC Local News 13 hours ago.
Padraig Harrington has been confirmed as Europe’s captain for the 2020 Ryder Cup at Whistling Straits.
Reported by Belfast Telegraph 13 hours ago.
Users in the UK and Europe as well as parts of the US were having difficulty with the app and found they were able to swipe left or right. Instead of profiles of a potential date appearing the Tinder users have been seeing a 'Error 5000' message.
Reported by MailOnline 12 hours ago.
A strong day for Europe and a jump in Wall Street futures kept world stocks at a three-week high on Tuesday, after Asia was knocked back by a shock profit warning from tech giant Samsung.
Reported by Reuters 12 hours ago.
Heavy snowfall brings widespread disruption to parts of Europe, Matt Taylor takes a look.
Reported by BBC News 12 hours ago.
The figures were in: 700,000 people had walked the streets of London in a demand for a second EU referendum, a so-called People’s Vote. Numbers matter when you’re marching. The bigger the better. Numbers are a key propaganda element in a demonstration. But counting march numbers can be tricky. You either give everyone a numbered ticket (so much for freedom) or count the numbers in a given area and multiply it by the length of the march; or count marchers as they pass a set point.
The number is the headline
The Guardian went big on the numbers. Its writers cheered on the “funky and fun” marchers. The belief was that a second referendum could only produce one victor: remain. The numbers do not lie. “It’s becoming ever clearer that Brexit is a far-right project. No wonder so many people are taking to the streets,” said one columnist. “Approaching 700,000 people marched on Saturday for a People’s Vote – from London’s Marble Arch to Parliament Square. The crowd seemed endless,” said another. A Labour peer “joined 700,000 people on the streets of London to demand a people’s vote on Brexit”. “So the will of the people was important until we discovered they lied to us,” says a child holding a ‘People’s Vote’ placard in the paper’s cartoon. The number stuck.
One month after the march, another columnist again linked Leave voters to the far-right: “Just over a month ago, 700,000 people marched for a people’s vote. Another Europe is Possible has, along with a series of prominent left figures, called for an explicitly anti-Brexit mobilisation on 9 December, which will build numbers for a joint general anti-fascist protest. If remainers mobilise, they could dwarf the pro-Brexit far right.” To say nothing of the pro-Brexit Tory centrists and working class would-be Labour Party voters, which he didn’t.
Like minds in agreement
The Independent told its readers: “More than 700,000 protesters and celebrities join second largest protest in UK this century.” What’s a protest by the people without a few famous faces? I confess to the joy of spotting a celebrity. “Demonstrators from across the UK heard speeches from household names including television presenter Delia Smith and London mayor Sadiq Khan.” Is the London mayor a celeb? The owner of Norwich City FC certainly is. Conservative MP Dominic Grieve might not be.
The Guardian placed a hand over one eye and added perspective. “The scale of today’s protest places it in the upper echelons of protests since the millennium,” readers learned. “A march organised by the Countryside Alliance in 2002 calling for Liberty & Livelihood reportedly attracted more than 400,000 people, while the TUC’s March for the Alternative anti-cuts protest in 2011 also saw around 400,000 people take to the streets.”
But then the truth seeped out – or at least something approaching the truth. The Telegraph cites a document by the Greater London Authority. It puts the number of people on the march closer to 250,000. Although it might be fewer if you don’t count the people caught up on the throng on their way to Hyde Park (i.e. me). Reported by Anorak 10 hours ago.
Hundreds trapped as winter weather causes flight delays and raises risks of more deadly avalanches
Reported by Independent 10 hours ago.
A sudden stratospheric warming event in the Arctic around Christmas, which can lead to a rush of cold air blowing eastwards across Europe a few weeks later, could bring much colder temperatures.
Reported by MailOnline 10 hours ago.
Vehicle market is a quarter larger than Europe’s, but sales are falling fast
Reported by FT.com 10 hours ago.
Iran's foreign minister said on Tuesday that EU sanctions on Tehran over alleged planned attacks in Europe "will not absolve Europe of responsibility for harboring terrorists."
Reported by Reuters 9 hours ago.
Passengers on a plane at London's Heathrow airport have been told that "things are starting to move", a witness told Reuters, after a drone sighting halted departures at Europe's biggest airport.
Reported by Reuters 8 hours ago.
Flights from London's Heathrow airport were halted on Tuesday after the airport said there had been sightings of a drone near Europe's busiest air hub.
Reported by Reuters 8 hours ago.
Heathrow resumed flights, a spokeswoman for Europe's biggest airport said, after departures were disrupted for an hour on Tuesday following reports of a drone sighting.
Reported by Reuters 8 hours ago.
Flights from London's Heathrow airport were halted for about an hour on Tuesday after reports of a drone sighting near Europe's busiest air hub, raising fears that the chaos that affected rival Gatwick last month could be repeated on an even larger scale.
Reported by Reuters 7 hours ago.
Will the CLA help Mercedes to tap into a younger, more tech-friendly audience?
New compact coupé's reveal at technology-based exhibition highlights ambitions for more youth appeal
How big is Texas? If you’ve ever wondered, good news: you’ll soon be able to Ask Mercedes.
Next question: why did Mercedes-Benz choose to launch the new CLA at the Consumer Electronics Show technology event in Las Vegas rather than at the Detroit motor show that takes place next week? I’ll field that one: because of the car’s younger, tech-friendly audience.
The CLA has been key to Mercedes increasing its appeal among more youthful buyers, particularly in the US, where the average CLA customer is 10 years younger than for any of its other models. In Europe, the average age of a CLA customer is also younger than for any other Mercedes, and half of all buyers of one previously owned another car firm’s vehicle. Crucially, according to Mercedes, 75% of CLA customers went on to buy another Mercedes as their next vehicle.
In other words, it is a conquest car, allowing Mercedes to win over younger customers - who could go on to buy several more of the firm’s cars. Reaching a more youthful market means pitching the CLA at a smartphone-savvy, Netflix-loving, internet-dwelling audience. So, as a result, Mercedes has packed the CLA with plenty of tech. Like the related A-Class, it receives infotainment systems previously only seen on the S-Class, including a host of advanced features.
So the reading lights can be controlled by waving a hand near the rear-view mirrow, an ‘energising coach’ system can sync with a Mercedes-Benz Vivoactive or Garmin smartwatch to recommend comfort settings (and even display driver’s pulses in the media display), and there’s the latest version of the Mercedes-Benz User Experience (MBUX) infotainment system.
That system includes the most advanced version of its Ask Mercedes system, which, the company says, can now respond to “more complex queries”. In its CLA press materials, the firm provided examples of such questions, which include how has the Apple share price performed compared with Microsoft, what is the square root of three and, yes, exactly how big Texas is (it’s 268,581 square miles, if you were wondering).
Okay, it’s not quite KITT, but it’s an intriguing step. Will the ability to ask your car complex queries add appeal to customers used to talking to their phones? Hmmm, that’s one to ask Mercedes in a few years…
*New CLA to be sportiest compact Mercedes yet*
*Mercedes-Benz CLA review*
*Mercedes EQ S to be flagship in £9bn electric model blitz* Reported by Autocar 7 hours ago.
The Nord Stream 2 pipeline is running into some trouble amid withering opposition from the Trump administration. Support for the Nord Stream 2 pipeline in Germany is slipping, according to a report from Bloomberg. Some politicians in Chancellor Angela Merkel’s coalition are moving against the pipeline for geopolitical reasons, citing fears that the project would allow Russia a freer hand in Ukraine. As it stands, Russia still needs to ship large volumes of gas to Europe via Ukraine. Nord Stream 2 would allow Russian gas to bypass Ukraine,…
Reported by OilPrice.com 2 hours ago.
London remained the top destination in Europe for technology investment in 2018, with nearly double the amount being plowed into companies in the British capital than nearest rival Berlin, data showed on Wednesday.
Reported by Reuters 1 hour ago.
New office expansion enables API to accelerate growth and increases the ability to service current and future markets.
MELVILLE, N.Y. (PRWEB) January 09, 2019
Accommodations Plus International (“API”), the worldwide leader of crew accommodation technology and service solutions, recently opened two new offices, located in Hong Kong and Sao Paolo. This global expansion positions API as the only Crew Accommodations Technology & Service provider with a presence in North America, South America, Europe, and APAC.
Global expansion to Hong Kong and Sao Paolo is a direct response to API’s continually expanding customer base within Asia and South America. The new offices enable API to continue in its mission to provide regional and local customers with exceptional service and exemplifying API’s commitment to providing their clients with the best layover experience for their crew.
In addition to the corporate headquarters in Melville, NY, the two new locations will employ 24/7 Operations Centers as well as a team of Account Managers, offering advantages for local talent acquisition and engaging global stakeholders.
“We are very excited to expand our global presence to better serve existing and new clients in these regions,” said Rich McLeer, CEO, API. “As our customer base expands, it is critical that we invest in excellent people, innovative technology and memorable service to provide best in class solutions to our clients and crew members”.
About Accommodations Plus International
Accommodations Plus International is the worldwide leader of crew accommodation solutions for the airline industry and other commercial clients. For more than 34 years, API has been offering a powerful combination of crew accommodation services delivered through innovative technology, unique software solutions, and a highly experienced team of service professionals. API enables clients to maximize savings in all areas of travel operations and makes sure their crew are happy, safe and secure every year! Additional information is available at http://www.apihotels.com Reported by PRWeb 2 hours ago.
Assignment of the “-fentrine” stem in the INN attests to RPL554’s dual phosphodiesterase inhibitor mechanism of action
LONDON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that the World Health Organization (“WHO”) approved “ensifentrine” as the recommended International Non-proprietary Name (“INN”) for the company’s drug candidate, RPL554.Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have bronchodilator as well as anti-inflammatory properties, and is currently in development for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”), cystic fibrosis (“CF”) and potentially asthma. The “-fentrine” stem indicates recognition from the WHO that RPL554 inhibits multiple phosphodiesterases, rather than a single phosphodiesterase, such as phosphodiesterase 3 or 4 alone.
“We are pleased to receive approval from the WHO for the use of ‘ensifentrine’, which to our knowledge, is the only molecule with an INN assignment using the ‘–fentrine’ stem currently in clinical development. We believe that this designation underlines our drug candidate’s position as a novel compound with a dual bronchodilator and anti-inflammatory mechanism of action,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “We are very encouraged by the positive data from our studies evaluating ensifentrine in COPD and CF, and look forward to advancing this novel drug candidate into late stage development as a potential new treatment for patients.”
“Ensifentrine is the only dual bronchodilator and anti-inflammatory drug candidate currently in development that I have come across in my research. This could be significant for patients and healthcare providers alike as there have been no new bronchodilator treatment classes over the last four decades,” said Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University.
In Phase 2 clinical trials completed to date, ensifentrine has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators, and has also shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. Verona Pharma is currently conducting two further Phase 2 clinical trials: one to evaluate a nebulized formulation of ensifentrine as an add-on treatment to dual LAMA/LABA therapy and triple LAMA/LABA/ICS therapy, and the other to evaluate a dry powder inhaler (“DPI”) formulation of ensifentrine for the maintenance treatment of COPD. The company also plans to evaluate ensifentrine in a metered-dose inhaler (“MDI”) formulation as part of a comprehensive clinical program intended to fully demonstrate the clinical utility of ensifentrine in improving the standard of care for COPD. These data will be used to support the planning of the ensifentrine Phase 3 COPD program.
*About Verona Pharma plc and ensifentrine
*Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In previous clinical trials, the nebulized formulation of ensifentrine has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators. It has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators, such as tiotropium (Spiriva^®), compared with such bronchodilators administered as a single agent. Ensifentrine improved FEV over four weeks in patients with moderate-to-severe COPD when compared to placebo and improved COPD symptoms and quality of life in a Phase 2b multicenter European study performed in 403 patients. In addition, ensifentrine has shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. Ensifentrine has been well tolerated in these studies and has shown a favorable safety and tolerability profile, having been administered to more than 730 subjects in 12 clinical trials. Verona Pharma is developing ensifentrine for the treatment of COPD, CF, and potentially asthma.
*This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding ensifentrine being the only molecule with an INN using the ‘–fentrine’ stem currently in clinical development, the INN underlining ensifentrine’s position as a novel compound with a dual mechanism of action, the advancement of ensifentrine into later stages of clinical development, including the use of data from the on-going Phase 2 studies in the planning of a Phase 3 program in COPD, ensifentrine’s treatment potential and potential indications, the significance of ensifentrine for patients and healthcare providers, plans to evaluate ensifentrine in an MDI formulation, and demonstrating the clinical utility of ensifentrine.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of ensifentrine, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of ensifentrine, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with ensifentrine which could adversely affect our ability to develop or commercialize ensifentrine; potential delays in enrolling patients, which could adversely affect our research and development efforts; we may not be successful in developing ensifentrine for multiple indications; our ability to obtain approval for and commercialize ensifentrine in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize ensifentrine; and lawsuits related to patents covering ensifentrine and the potential for our patents to be found invalid or unenforceable. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on February 27, 2018, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
*For further information, please contact:*
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer email@example.com
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker) Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins firstname.lastname@example.org
ICR, Inc. (US Media and Investor enquiries)
Tel: +1 203-919-7905
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com Reported by GlobeNewswire 2 hours ago.
Brussels has warned British Airways owner IAG that its favoured strategy to allow it to continue flying freely in and around Europe in the event of a no-deal Brexit will not work.
Reported by MailOnline 2 hours ago.